EP2655619A4 - Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms - Google Patents

Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms

Info

Publication number
EP2655619A4
EP2655619A4 EP10861010.6A EP10861010A EP2655619A4 EP 2655619 A4 EP2655619 A4 EP 2655619A4 EP 10861010 A EP10861010 A EP 10861010A EP 2655619 A4 EP2655619 A4 EP 2655619A4
Authority
EP
European Patent Office
Prior art keywords
neoplasms
treatment
combination therapy
inhibitor combination
autophagy inducer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10861010.6A
Other languages
German (de)
French (fr)
Other versions
EP2655619A1 (en
Inventor
Kui Lin
Michael Degtyarev
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of EP2655619A1 publication Critical patent/EP2655619A1/en
Publication of EP2655619A4 publication Critical patent/EP2655619A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP10861010.6A 2010-12-23 2010-12-23 Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms Withdrawn EP2655619A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2010/062096 WO2012087336A1 (en) 2010-12-23 2010-12-23 Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms

Publications (2)

Publication Number Publication Date
EP2655619A1 EP2655619A1 (en) 2013-10-30
EP2655619A4 true EP2655619A4 (en) 2014-10-22

Family

ID=46314300

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10861010.6A Withdrawn EP2655619A4 (en) 2010-12-23 2010-12-23 Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms

Country Status (9)

Country Link
EP (1) EP2655619A4 (en)
JP (1) JP2014507129A (en)
KR (1) KR20130132956A (en)
CN (1) CN103403161A (en)
BR (1) BR112013015891A2 (en)
CA (1) CA2821378A1 (en)
MX (1) MX2013007171A (en)
RU (1) RU2013134359A (en)
WO (1) WO2012087336A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6052540B2 (en) * 2012-12-21 2016-12-27 国立大学法人福井大学 Method for inhibiting autophagy using ATG7 mutant
JP6441232B2 (en) 2012-12-27 2018-12-19 サノフイＳａｎｏｆｉ Anti-LAMP1 antibodies and antibody drug conjugates and uses thereof
KR101461916B1 (en) 2013-11-04 2014-11-19 현대자동차 주식회사 Coupled torsion beam axle type suspension system
US11986480B2 (en) 2017-02-03 2024-05-21 Tohoku University Heterocyclic compound
WO2018226776A1 (en) * 2017-06-08 2018-12-13 The Penn State Research Foundation Assay for monitoring autophagosome completion
JPWO2019112014A1 (en) * 2017-12-07 2021-01-28 パール工業株式会社 Method of introducing selected molecule and composition containing inhibitor
CN108103194B (en) * 2017-12-27 2021-05-18 中国医学科学院药用植物研究所 Target for inhibiting gastric cancer cell MGC-803 and application thereof
KR102095749B1 (en) * 2018-12-20 2020-04-01 충남대학교 산학협력단 Composition for prevention or treatment of a disease occured by autophagy disorder in mitochondria comprising expression inhibitors of S6K1 gene or activity inhibitors of S6K1 protein
CN111593068B (en) * 2019-01-28 2023-10-17 广州溯原生物科技股份有限公司 Preparation method and application of novel gene therapy vector pIRES-Rsirt2/4-Tet-nap
CN110592044B (en) * 2019-07-26 2021-06-22 中国农业科学院蔬菜花卉研究所 Protein kinase Fused coding gene and application thereof in preventing and treating diamond back moth

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008006040A1 (en) * 2006-07-06 2008-01-10 Array Biopharma Inc. Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1856247B1 (en) * 2005-01-19 2016-05-04 The Trustees of The University of Pennsylvania Regulation of autophagy and cell survival
JP2009502954A (en) * 2005-07-27 2009-01-29 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド Small molecules to correct protein misfolding and uses thereof
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US20100021420A1 (en) * 2006-07-14 2010-01-28 Astex Therapeutics Limited Combinations of pyrazole derivatives for the inhibition of cdks and gsk's
US8476431B2 (en) * 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
EP2439274A4 (en) * 2009-06-05 2013-11-06 Dai-Wu Seol MULTI-CISTRONIC shRNA EXPRESSION CASSETTE FOR SUPPRESSING SINGLE OR MULTIPLE TARGET GENES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008006040A1 (en) * 2006-07-06 2008-01-10 Array Biopharma Inc. Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEN S ET AL: "Autophagy is a therapeutic target in anticancer drug resistance", BBA - REVIEWS ON CANCER, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 1806, no. 2, 1 December 2010 (2010-12-01), pages 220 - 229, XP027527118, ISSN: 0304-419X, [retrieved on 20100713] *
FAN QI-WEN ET AL: "Akt and Autophagy Cooperate to Promote Survival of Drug-Resistant Glioma", SCIENCE SIGNALING, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 3, no. 147, 9 November 2010 (2010-11-09), pages 11pp, XP009158787, ISSN: 1945-0877, DOI: 10.1126/SCISIGNAL.2001017 *
See also references of WO2012087336A1 *
SHI-YONG SUN: "Enhancing perifosine's anticancer efficacy by preventing autophagy", AUTOPHAGY, vol. 6, no. 1, 1 January 2010 (2010-01-01), pages 184 - 185, XP055139450, DOI: 10.4161/auto.6.1.10816 *
Z. WU ET AL: "Autophagy Blockade Sensitizes Prostate Cancer Cells towards Src Family Kinase Inhibitors", GENES & CANCER, vol. 1, no. 1, 1 January 2010 (2010-01-01), pages 40 - 49, XP055139460, ISSN: 1947-6019, DOI: 10.1177/1947601909358324 *

Also Published As

Publication number Publication date
WO2012087336A1 (en) 2012-06-28
MX2013007171A (en) 2013-11-04
JP2014507129A (en) 2014-03-27
EP2655619A1 (en) 2013-10-30
KR20130132956A (en) 2013-12-05
RU2013134359A (en) 2015-01-27
BR112013015891A2 (en) 2016-10-04
CN103403161A (en) 2013-11-20
CA2821378A1 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
IL261768B (en) Devices and methods for the treatment of tissue
EP2655619A4 (en) Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms
HK1210957A1 (en) Effluz inhibitor compositions and methods of treatment using the same
GB2478595B (en) Phytocannabinoids in the treatment of glioma
IL225471A0 (en) Compositions and methods for the prevention and treatment of cancer
HK1173654A1 (en) Therapeutic compounds and related methods of use
EP2558085A4 (en) Compositions and methods for the prevention and treatment of cancer
HRP20181879T1 (en) Compounds for the treatment of obesity and methods of use thereof
IL225793A0 (en) Methods and compositions for the treatment of insulin-associated medical conditions
GB201005662D0 (en) Phototherapeutic treatment of acne
ZA201300762B (en) Novel combination therapy for the treatment of cancer
EP2651894A4 (en) Thiosemicarbazone compounds and use in the treatment of cancer
IL231234A0 (en) Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases
EP2624821A4 (en) Combination therapy for the treatment of depression and other non-infectious diseases
ZA201501503B (en) Bio-inoculant and use thereof for treatment of effluents
EP2575824A4 (en) Methods for the treatment and prevention of inflammatory diseases
IL275636A (en) Therapeutic combination for the treatment of cancer
WO2012097121A9 (en) Specific nnos inhibitors for the therapy and prevention of human melanoma
PT2637974T (en) Multifunctional composition for the disinfection treatment of water and use of this composition
SG11201405113VA (en) Systems and methods for the treatment of ballast water
PT2389936E (en) Aminaphtone for use in the treatment and/or prevention of migraine
TH164734B (en) Spiro-oxindol compounds And the use of these substances as therapeutic agents

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130722

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

A4 Supplementary search report drawn up and despatched

Effective date: 20140922

RIC1 Information provided on ipc code assigned before grant

Ipc: C07H 21/04 20060101ALI20140916BHEP

Ipc: C12N 15/11 20060101AFI20140916BHEP

17Q First examination report despatched

Effective date: 20160531

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160701